Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Paclitaxel 337 pembrolizumab 332 Carboplatin 329 Cisplatin 276 Gemcitabine 264 Docetaxel 251 Bevacizumab 239 Nivolumab 230 Pemetrexed 210 Rituximab 183 Dexamethasone 183 Cyclophosphamide 169 Capecitabine 169 Trastuzumab 149 Fluorouracil 147 Ipilimumab 121 atezolizumab 118 Prednisone 117 Erlotinib Hydrochloride 116 Oxaliplatin 109 Cetuximab 104 Sunitinib 101 Leucovorin 97 Doxorubicin 97 Lenalidomide 93 Irinotecan 89 130-nm albumin-bound paclitaxel 84 durvalumab 77 Bortezomib 77 Azacitidine 73

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Has results × RAD1901 × Clear all

NCT03778931 2025-09-15

EMERALD

Stemline Therapeutics, Inc.

Phase 3 Completed

478 enrolled 16 charts 1 FDA

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡